Zobrazeno 1 - 10
of 409
pro vyhledávání: '"H Rochant"'
Autor:
Joël Ceccaldi, Jean-Pierre Marie, Geneviève Marguerite, Dominique Bordessoule, Sylvie Gervaise, Dominique Jaulmes, Jean-Yves Cahn, H. Rochant, Philippe Casassus, Jean-Jacques Sotto, Philippe Colombat, Robert Zittoun, Christian Bastard
Publikováno v:
Hématologie. 20:12-21
Les recommandations de la Societe de Reanimation en Langue Francaise (SRLF) [1], publiees en 2002, concernant les limitations et arrets de therapeutiques actives en reanimation adulte, sont a ce jour une initiative unique qui a modifie les pratiques
Autor:
Philippe Colombat, Marc Zandecki, Robert Zittoun, Philippe Casassus, Eric Fiat, Jean-Jacques Sotto, Dominique Bordessoule, Diane Damotte, Joël Ceccaldi, Chantal Bauchetet, Jean-Pierre Jouet, Dominique Jaulmes, H. Rochant, Morgane Cheminant, Alice Polomeni, Christian Bastard, Sandra Malak, Sarah Morin, Geneviève Margueritte
Publikováno v:
Hématologie. 17:243-247
hma.2011.0608 Auteur(s) : Chantal Bauchetet, Dominique Bordessoule, Philippe Casassus, Joel Ceccaldi, Morgane Cheminant, Christian Bastard, Philippe Colombat, Diane Damotte, Eric Fiat, Dominique Jaulmes, Jean-Pierre Jouet, Sandra Malak, Genevieve Mar
Publikováno v:
La Revue de Médecine Interne. 23:901-909
Resume Propos. – Decrire les principales caracteristiques et les modalites evolutives des anemies hemolytiques auto-immunes (AHAI) de l’adulte et evaluer la pertinence et la rentabilite des examens complementaires realises a la recherche d’une
Autor:
Joël Ceccaldi, Robert Zittoun, Morgane Cheminant, Sandra Malak, Philippe Casassus, Jean-Jacques Sotto, Philippe Colombat, H. Rochant, Dominique Bordessoule, Yvan Beaussant, Dominique Jaulmes
Publikováno v:
Advances in Hematology, Vol 2014 (2014)
Advances in Hematology
Advances in Hematology
Admission of patients with hematological malignancies to intensive care unit (ICU) raises recurrent ethical issues for both hematological and intensivist teams. The decision of transfer to ICU has major consequences for end of life care for patients
Autor:
Eric Solary, Pascale Lepelley, N. Gratecos, Philippe Casassus, Jean-Pierre Jouet, Francois Dreyfus, Xavier Leleu, Agnès Guerci, Pauline Brice, H. Rochant, L. Hoang-Ngoc, Annie Brion, Pierre Fenaux, Frédéric Maloisel, M. Janvier, Eric Wattel
Publikováno v:
Leukemia. 13:524-529
A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes
Publikováno v:
La Revue de medecine interne. 23(11)
To describe the main characteristics and outcome of adult's acquired immune hemolytic anemias (AIHA). To analyse the relevance of the complementary tests performed for the search of an underlying disease.Retrospective (1980-2000) monocentric study.ag
Autor:
H, Rochant
Publikováno v:
La Revue du praticien. 51(14)
From the beginning of the century, autoimmune haemolytic anaemia (AIHA) was the first model of an auto-antibody mediated disease. Despite the variety of the clinical features, the diagnosis of AIHA provides few difficulties since the introduction of
Autor:
Herve Tilly, B. Christian, Philippe Cassasus, H. Rochant, Francis Bauters, Pierre-Yves Le Prise, Jean-Francois Abgrall, Gerard Dine, Jean-Luc Harousseau, F. Guilhot, J. P. Lamagnere, Pauline Brice, Brigitte Duclos, Norbert Ifrahy, Agnès Guerci, Joseph Tanzer
Publikováno v:
Leukemia & Lymphoma. 11:181-183
The CML 88 study was designed to evaluate the efficacy of maintenance therapy in a multicentric randomised protocol using IFN combined with low-dose Ara-C versus IFN alone, following an induction with IFN + HU. Between April 1988 and February 1991, 2
Autor:
E, Wattel, E, Solary, B, Hecquet, D, Caillot, N, Ifrah, A, Brion, N, Milpied, M, Janvier, A, Guerci, H, Rochant, C, Cordonnier, F, Dreyfus, A, Veil, L, Hoang-Ngoc, A M, Stoppa, N, Gratecos, A, Sadoun, H, Tilly, P, Brice, B, Lioure, B, Desablens, B, Pignon, J P, Abgrall, M, Leporrier, P, Fenaux
Publikováno v:
Advances in experimental medicine and biology. 457
We designed a randomized trial of IC with or without quinine, an agent capable of reverting the multidrug resistance (mdr) phenotype, in patients agedor = 65 years with high risk MDS. Patients were randomized to receive Mitoxantrone 12 mg/m2/d d2-5 +